Search

Amaç: Bu çalışmada Bursa ilinde Alzheimer hastalarına bakım veren bireylerin hastalıkla ilgili farkındalık düzeyinin araştırılması amaçlanmıştır.Gereç ve Yöntem: Orta veya ağır evre Alzheimer hastasına en az 6 aydır bire bir bakım veren 50 kişi çalışmaya dahil edildi. Hastaların ve bakım verenlerin demografik özellikleri kayıt altına alındı. Bakım verenlere hastalıkla ilgili basit temel bilgilerin sorgulandığı 10 soruluk bir anket uygulandı.Bulgular: Katılımcıların %56’sı hastalıkla karşılaşmadan önce hastalıkla ilgili bilgiye sahip değildi. %50’si yakını Alzheimer tanısı aldıktan sonra hastalıkla ilgili bilgi almak için herhangi bir yönteme başvurmamıştı. Katılımcıların %84’ü hastalığın kalıcı olduğunu, %80’i tedavisinin ilaçlarla yapıldığını bilmekteydi. %86’sı ilaçların şikayetleri sadece kısmen geriletmek için verildiğinin farkındaydı. %54’ü ağızdan alınan tabletler dışında başka tedavi seçeneklerinden haberdar değildi. %44’ü tedaviyle hastalığın düzelmediğini, %50’si ilaçları dönem dönem değiştirmek gerektiğini bilmekteydi. Hastalıkla ilgili sizi en çok sıkıntıya sokan şey nedir sorusuna sırasıyla gece uykusuzluğu, ajitasyonlar, inatçılık, hırçınlık, idrar ve gaita inkontinansı cevapları verildi. Sonuç: Hasta yakınlarının hastalıkla ilgili yeterli bilgiye sahip olması hastalığın erken tanınması, hastalığa bağlı gelişen problemlerin anlaşılabilmesi ve tedavi sürecinin düzgün yönetilmesine olanak sağlayacaktır

Aim: The aim of the study is to investigate the effect of diabetes mellitus (DM) on non-motor symptoms in Parkison’s Disease (PD). Patients and Methods: The study included 73 patients with DM and 30 without DM who were followed-up with the diagnosis of PD at the neurology outpatient clinic. The United Parkinson's Disease Rating Scale (UPDRS) and Hoehn Yahr Staging (HYE) was performed. In both groups Non-motor Symptoms Questionnaire (NMSQ), Beck Depression Inventory (BDI), Hamilton Anxiety Inventory (HAI), Pitsburg Sleep Quality Scale (PSQI), Epworth Sleepiness Scale (ESS) and Insomnia Severity Index (ISI) were performed. Results: There was no significant difference between the two groups in terms of HAI, BDI, ISI and ESS scores. There was no significant difference in the rates of depression, anxiety disorders and daytime sleepiness in the groups with and without DM. According to the PSQI, the ratio of those with poor sleep was the same. When all the questions of the non-motor symptoms questionnaire were evaluated separately, the ratio of those who answered yes to the question ‘’Was there excessive sweating?’’ was significantly higher in the diabetic group (p = 0.036). The risk of excessive sweating in patients with PD who had DM was 13 times higher than those without DM. Coclusion: DM is a parameter that increases the rate of excessive sweating in patients with PD.

Objective:We aimed to evaluate the frequency and severity of restless legs syndrome in patients with asthma and the effect of the disease on sleep quality.Materials and Methods:Forty-three patients followed by asthma and 30 healthy people were included in the study. The diagnosis of Restless Legs Syndrome was made according to the criteria of the International Restless Legs Syndrome Study Group. Excessive daytime sleepiness scores were determined according to the Epworth Sleepiness Scale (ESS). According to the Pittsburgh Sleep Quality Index (PSQI) the sleep quality and according to the Insomnia Severity Index (ISI) the insomnia was determined.Results:Male/female rate in the asthmatic group was 1/8, and the mean age was 48.88 years. The healthy control group was selected to be gender and age-matched. Restless Legs syndrome was found 25.58% (n=11) in the asthmatic group and 16.7% (n=5) in the control group, and it was also not statistically significant. The number of asthmatic patients with ESS ≥10 was six, while there was one person in the control group, and it was not statistically significant. According to the PSQI values, there was a significant difference between the asthmatic group and the control group (p

Malignancy, immunosuppressive drug use, and diabetes mellitus (DM) are defined as risk factors for herpes zoster. A 58-year-old male patient with the diagnosis of DM was admitted to the emergency room with the complaints of double vision. His neurological examination revealed under activity of the right lateral rectus muscle and hypoactive deep tendon reflexes. In this report, we discuss a rare case of isolated abducens nerve palsy that occurred after postviral infection in the patient.

Background: Parkinson's disease is a neurodegenerative disease. Cognitive disorders and retinal degeneration may occur during the early stages of the disease. Retinal degeneration and cognitive findings can be assessed easily with optical coherence tomography and mini–mental test, respectively. Materials and Methods: Twenty-two patients who are being followed-up with Parkinson's disease and 22 healthy controls have been included in the study. The Unified Parkinson's Disease Rating Scale (UPDRS) and Hoehn–Yahr staging of the patients have been conducted at the time of admission. Retinal nerve fiber layer analysis and ganglion cell thickness (ganglion cell complexes [GCCs]) were evaluated through optical coherence tomography (OCT). And at the same time, we aimed to compare the stage of the disease, the UPDRS score and the duration of the disease with OCT and cognitive functions by mini–mental test. Results: Mini–mental test total score value (P = 0.025) and language value (P = 0.021) were lower in the patient group compared to the control group. In patients, there is a reverse significant correlation between UPDRS-T and GCC-left-superior (r = −0.495; P = 0.026), GCC-left-inferior (r = −0.517; P = 0.019), and GCC-left-to (r = −0.508; P = 0.022). There is a significant parallel relation between recall and RFNL-right-mean (r = 0.626; P = 0.039). Conclusion: Our findings indicate that the neurodegeneration continues multisystemically and neurodegeneration increases simultaneously with the disease. OCT, which is a noninvasive method, can be used as an indicator of neurodegeneration in patients with Parkinson's disease.